Latest news from the FASST trial
The purpose of this study is to evaluate the effectiveness and safety of IVA337 for the treatment of Diffuse Cutaneous Systemic Sclerosis.
Read latest newsletter on the research: FASST Newsletter, May2016
news & events
FESCA is proud to be a partner of a the new This is Living campaign launched last month by Boehringer Ingelheim.
We are happy to share with you our latest newsletter. Read about World Scleroderma Day 2021, projects, our next world congress and more.
BMJ presents a series of webinars on the topic medical records.